

Evaluation of 177Lu-Dotatate treatment in patients with meta:



ALL

IMAGES

VIDEOS

关闭取词

29,800 Results

Any time ▾

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa1607427>

In **patients** with midgut **neuroendocrine tumors** that progressed during octreotide analogue therapy, the addition of **177Lu-Dotatate** to octreotide resulted in an 18% response rate and a significantly h...

Cited by: 780

Author: Jonathan Strosberg, G. El-Haddad, Edwar...

Publish Year: 2017

Neuroendocrine Tumor Therapy: 177Lu-DOTATATE : ...

<https://www.ajronline.org/doi/10.2214/AJR.18.19953>

Patient selection is based on a number of specific **factors** and should be sequenced carefully with respect to other available therapies, ideally in multidisciplinary **cancer** conferences. Establishing the therapy at a **new** institution can be somewhat involved, but once it is established, the therapy is fairly straightforward to administer and is ...

Cited by: 6

Author: Erik S. Mittra

Publish Year: 2018

Clinical utility of 177 Lu-DOTATATE PRRT in somatostatin ...

https://www.researchgate.net/publication/337454380_Clinical_utility_of_177_Lu-DOTATATE...

Cabozantinib (140 mg per day) achieved a statistically significant improvement of **PFS** in **patients** with **progressive metastatic MTC** and represents an important new **treatment** option for **patients** with ...

Therapy for metastatic pancreatic neuroendocrine tumors

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200651>

In **patients** with **pNETs**, **assessment** of the **tumor** extent and location as well as **evaluation** of prognostic factors and patient's performance status and comorbidities are required to define the **proper treatment** (18-20). The **evaluation** of the **tumor** extent and the identification of the exact site of the primary and **metastatic lesions** are necessary to decide whether a curative surgical approach is ...

Cited by: 18

Author: Roberta Elisa Rossi, Sara Massironi, Dari...

12

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 53145

Manuscript Type: ORIGINAL ARTICLE

Observational Study

Evaluation of ¹⁷⁷Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors

Estephany Abou Jokh Casas, Virginia Pubul, Urbano Anido-Herranz, María del Carmen Mallón, Maria del Carmen Pombo, Miguel Garrido, José Manuel Cabezas, José Manuel Cameselle, Ashraf Hilal, Álvaro Ruibal

Abstract

Match Overview

Rank	Source	Words	Matched Words	Percentage
1	Internet	97 words	1940	2%
	crawled on 06-Dec-2018 jnm.snmjournals.org			
2	Internet	78 words	780	1%
	crawled on 04-Dec-2019 www.mdpi.com			
3	Internet	56 words	560	1%
	crawled on 25-Nov-2017 repub.eur.nl			
4	Internet	39 words	390	1%
	crawled on 10-Sep-2018 link.springer.com			
5	Internet	35 words	350	1%
	crawled on 11-Oct-2019 www.ajronline.org			
6	Internet	34 words	340	1%
	crawled on 19-Mar-2014 www.ncbi.nlm.nih.gov			
7	Crossref	32 words	320	1%
	Martijn Essen. "Peptide receptor radionuclide therapy with ¹⁷⁷ Lu-octreotate in patients with foregut carcinoid tumours ..."			
8	Crossref	24 words	240	<1%
	Gulenchyn, K.Y. "Radionuclide Therapy in Neuroendocrine Tumours: A Systematic Review", <i>Clinical Oncology</i> , 201205			

国内版

国际版

Evaluation of ¹⁷⁷Lu-Dotatate treatment in patients with meta:



ALL

IMAGES

VIDEOS

51,000 Results

Any time ▾

Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa1607427>

In **patients with midgut neuroendocrine tumors** that progressed during **octreotide analogue therapy**, the addition of **¹⁷⁷Lu-Dotatate** to **octreotide** resulted in an 18% response rate and a significantly h...

Treatment with ¹⁷⁷Lu-DOTATOC of Patients with Relapse of ...

jnm.snmjournals.org/content/46/8/1310.full

Aug 01, 2005 · The study included 27 **patients** with metastasized **tumors**, 11 of whom had **neuroendocrine pancreatic tumors** and 16, **neuroendocrine tumors** of other sites (7 of the small bowel, 4 of unknown primary, 2 of the rectum, 1 of the stomach, 1 of the bronchus, and 1 of the appendix).

Cited by: 171

Author: Flavio Forrer, Helena Uusijärvi, Daniel St...

Publish Year: 2005

Therapy With ¹⁷⁷Lu-DOTATATE: Clinical Implementation and ...

<https://www.ajronline.org/doi/abs/10.2214/AJR.19.21123>

Bergsma H, van Lom K, Raaijmakers MH, et al. Persistent hematologic dysfunction after peptide receptor radionuclide therapy with **¹⁷⁷ Lu-DOTATATE**: incidence, course, and predicting **factors in patients** with gastroenteropancreatic **neuroendocrine tumors**.

Author: Ayse Tuba Kendi, Thorvardur R Halfd...

Publish Year: 2019

Neuroendocrine Tumor Therapy with Lutetium-177: A ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443107>

Jan 30, 2019 · **Patients** with localized NETs are treated with surgery, but 40% of **patients** already have metastasized disease at diagnosis and require systemic **treatment**. Targeted therapy has been utilized

Evaluation of 177Lu-Dotatate treatment in patients with meta



YJ



ALL

IMAGES

VIDEOS

49,300 Results

Any time ▾

Treatment with 177Lu-DOTATOC of Patients with Relapse of ...

jnm.snmjournals.org/content/46/8/1310.full

Aug 01, 2005 · Therapy with [90 Y-DOTA 0, Tyr 3]-octreotide (**DOTATOC**, where **DOTA** = tetraazacyclododecane tetraacetic acid and **TOC** = **d-Phe-c**(Cys-Tyr-d-Trp-Lys-Thr-Cys)-Thr(ol)) is established for the treatment of metastatic neuroendocrine tumors. Nevertheless, many patients experience disease relapse, and further treatment may cause renal failure.

Cited by: 171

Author: Flavio Forrer, Helena Uusijärvi, Daniel St...

Publish Year: 2005

Neuroendocrine Tumor Therapy with Lutetium-177: A ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443107>

Jan 30, 2019 · **Patients** with localized NETs are treated with surgery, but 40% of **patients** already have metastasized disease at diagnosis and require systemic **treatment** . Targeted therapy has been utilized to treat these **tumors**, which includes somatostatin analogs (SSAs) and peptide receptor radionuclide therapy (PRRT), as these **tumors** express SSTRs.

Cited by: 1

Author: Muhammad Haisum Maqsood, Asim Tam...

Publish Year: 2019

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine